$PFE [The BioNTech and Pfizer data was particularly promising] The companies said in late July that they were beginning a The BioNTech and Pfizer data was particularly promising. The companies said in late July that they were beginning a Phase 2/3 trial of BNT162b2, one of two similar versions of the vaccine they had developed. But the companies had only released Phase 1 data on the other version, called BNT162b1. The paper out Thursday outlines the results of the BNT162b2 test, and says that while the immune responses elicited by the two vaccines were similar, the second version had a better safety profile.
“The data set presented here guided our decision to advance BNT162b2... into the Phase 2/3,” the paper reads. “The primary consideration driving this decision was the milder systemic reactogenicity profile of BNT162b2, particularly in older adults, in the context of comparable antibody responses elicited by both candidate vaccines.”of BNT162b2, one of two similar versions of the vaccine they had developed. But the companies had only released Phase 1 data on the other version, called BNT162b1. The paper out Thursday outlines the results of the BNT162b2 test, and says that while the immune responses elicited by the two vaccines were similar, the second version had a better safety profile.
Market Data 
Markets 
AI
